FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
comments(0)
5-min edit window · permanent after that